R&D Pipeline

Aptamer Technology Disease Indication Discovery Pre-Clin Dev P1 P2
BT200 Hemophilia
BT200 vWD
BT101 BT200 reversal agent
BT600 Sickle Cell Disease
Targeted CpG Immunostimulation Oncology
Aptamer Toxin Conjugates Oncology
Bi-Specific Modality Oncology
Oral Administration GI
Oral Administration Infectious Disease

Contact

© 2021 Guardian Therapeutics. All rights reserved.

Headquarters
Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580

General Inquiries:
info@guardian-rx.com

Business Development Inquiries: businessdevelopment@guardian-rx.com